Crinetics Pharmaceuticals, Inc. announced on February 24, 2025, the appointment of Tobin 'Toby' Schilke as Chief Financial Officer, effective February 28, 2025. Mr. Schilke brings over 25 years of global pharmaceutical experience to the role.
Mr. Schilke's prior experience includes transforming biotech companies from R&D-focused entities into fully integrated commercial organizations, and he has successfully executed over $1.5 billion in equity, convertible debt, and structured debt financing. He previously served as CFO at Revance Therapeutics and Achaogen.
This executive appointment is critical as Crinetics prepares for its first commercial launch and advances numerous promising candidates through development. Mr. Schilke's financial leadership is expected to accelerate the company's growth objectives and create long-term value during this transformative stage.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.